GENE ONLINE|News &
Opinion
Blog

Gene Editing
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Verve Cleared to Test Gene Editing Drug for Heart Disease in Humans
2022-05-12
TALED Tool Launches a New Era of Mitochondrial Genome Editing
2022-05-03
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
What If Our Body’s Power Station Goes Wrong? Gene Therapy May Help
2022-02-15
GeneOnline’s Pick: Novel Biotechnologies that Made a Splash in 2021
2022-01-27
GeneOnline’s Top 10 Editor’s Picks for 2021
2021-12-23
Harnessing the potential of CRISPR-Cas9 for Gut Microbiome Gene Editing
2021-11-29
Study Advocates Cautious Application of CRISPR in Designing Therapeutics
2021-11-22
Chroma Medicine Debuts with High Hopes for “Game-Changing” Epigenetic Genome Editors
2021-11-17
Moderna Enters Gene Editing Market with Metagenomi Collaboration
2021-11-03
New Age Gene Editors Take Us Closer to CRISPR-Based Gene Therapy
2021-10-28
Vertex Signs $700 Million worth CRISPR Pact with Jennifer Doudna Co-founded Gene Editing Firm
2021-10-26
1 2 3 6
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!